Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 8/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | HRH2 | P25021 | 1/20 | 0.55 |
| ▸ | HTR1B | P28222 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HTR1E | P28566 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22291054 | 0.95 | CA1 (0.55) | CA1CA2CA7CA9MEN1 | |
| SCHEMBL9727540 | 0.88 | NPSR1 (0.68) | CA1CA2CA7CA9MEN1 | |
| SCHEMBL6132364 | 0.87 | GAA (0.69) | CA1CA2CA7CA9MEN1 | |
| SCHEMBL6805752 | 0.86 | TMEM97 (0.55) | CA1CA2CA7CA9MEN1 | |
| SCHEMBL19950156 | 0.84 | MEN1 (0.60) | CA1CA2CA7CA9MEN1 | |
| SCHEMBL975238 | 0.84 | NPSR1 (0.60) | CA1CA2CA7CA9MEN1 | |
| SCHEMBL894510 | 0.84 | MEN1 (0.60) | CA1CA2CA7CA9MEN1 | |
| SCHEMBL12814257 | 0.84 | MEN1 (0.60) | CA1CA2CA7CA9MEN1 | |
| SCHEMBL23446655 | 0.84 | CA1 (0.58) | CA1CA2CA7CA9MEN1 | |
| SCHEMBL8642538 | 0.83 | MEN1 (0.59) | CA1CA2CA7CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-01-14 | — | — | US | disclosed |
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| CN-112867706-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3802489-A2 | MASP-2 INHIBITORS AND METHODS OF USE | Omeros Corporation (US) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CA1 3685/4885CA2 2623/4885CA7 3548/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CA1 3685/4885CA2 2623/4885CA7 3548/4885 |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CA1 3685/4885CA2 2623/4885CA7 3548/4885 |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CA1 3685/4885CA2 2623/4885CA7 3548/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CA1 3513/4885CA2 2522/4885CA7 3583/4885 |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CA1 3685/4885CA2 2623/4885CA7 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.